Hunan Er-Kang Pharmaceutical Co., Ltd (SHE:300267)

China flag China · Delayed Price · Currency is CNY
3.450
+0.050 (1.47%)
Jun 12, 2026, 3:06 PM CST
Market Cap7.12B +10.6%
Revenue (ttm)1.06B -13.0%
Net Income-394.82M
EPS-0.19
Shares Out 2.06B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume41,574,000
Open3.350
Previous Close3.400
Day's Range3.350 - 3.500
52-Week Range3.010 - 5.110
Beta0.41
Analystsn/a
Price Targetn/a
Earnings DateAug 28, 2026

About SHE:300267

Hunan Er-Kang Pharmaceutical Co., Ltd engages in the research and development, production, and sale of pharmaceutical excipients, APIs and finished drugs in China and internationally. The company offers various APIs, such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, dihydroxypropyl theophylline, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. It also provides finished drugs, including sulbenicillin sodium for injection and compound liquorice tablets. In addition, the company offers conventional pharmaceutica... [Read more]

Sector Healthcare
Founded 2003
Employees 1,271
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300267
Full Company Profile

Financial Performance

In 2025, SHE:300267's revenue was 1.17 billion, an increase of 2.29% compared to the previous year's 1.14 billion. Losses were -379.82 million, 1.73% more than in 2024.

Financial Statements